HIV Policy and AdvocacyConference Coverage

The Medicines Patent Pool (MPP) Broadens Collaboration With Gilead Sciences: Signs License for Phase III Medicine Tenofovir Alafenamide (TAF)

Announced at the 20th International AIDS Conference in Melbourne, the Agreement Seeks to Increase Access to a Promising New HIV Medicine in 112 Developing Countries

    Medicines Patent Pool